🚨 #OCUGEN just hit a major milestone!
The largest gene-agnostic #RetinitisPigmentosa trial is now fully enrolled. ✅
The roadmap is clear:
1️⃣ Enrollment complete
2️⃣ Patient follow-up underway
3️⃣ Top-line results ahead
The countdown to potentially changing the future of RP treatment has officially begun. 🔥
#OCU400 #GeneTherapy #Biotech #VisionRestoration #LETSGOOO
https://t.co/T30ICpFqul
🚨 Game-changer for Retinitis Pigmentosa patients!
Ocugen’s OCU400 — the first gene-agnostic modifier gene therapy for RP — just received major EMA support:
✅ Positive ATMP classification ✅ Phase 3 trial design accepted for European Marketing Authorization Application !
Phase 3 enrollment complete. MAA filing planned 1-3 Months after BLA filling → potential conditional approval in Europe H2 2027?
A one-time treatment that could help patients across dozens of genetic mutations. Real hope for a disease with almost no options. 👁️🧬
Repost it, if this gives you hope for gene therapy!
#OCU400 #RetinitisPigmentosa #GeneTherapy #Ocugen #EMA #Blindness #Biotech #OCU400 #RetinitisPigmentosa #GeneTherapy #Ocugen #EMA